We recently received authorization from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for our Phase 1/2 clinical study evaluating mRNA-4194, an investigational mRNA-based vaccine for people with Lynch syndrome, an inherited condition that increases the risk of cancer.

David Berman, our Chief Development Officer, sat down for an episode of IR Insights to provide an overview of this innovative program and Moderna’s research in the cancer prevention vaccine space: https://www.modernatx.com/media-center/all-media/blogs/potential-mRNA-cancer-prevention